WRF
LGND icon

Waddell & Reed Financial’s Ligand Pharmaceuticals LGND Stock Holding History

Waddell & Reed Financial’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-29,816
Closed -$1.9M – 603
2016
Q3 		$1.9M Hold
29,816
– – ﹤0.01% 566
2016
Q2 		$2.22M Hold
29,816
– – ﹤0.01% 557
2016
Q1 		$1.99M Buy
+29,816
New +$1.81M ﹤0.01% 575

Other funds holding LGND

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Waddell & Reed Financial's LGND Position: Q4 2016 in Review

Waddell & Reed Financial sold out of Ligand Pharmaceuticals (LGND) in Q4 2016, closing a stake of 29,816 shares — an estimated $1.9M sold.

Waddell & Reed Financial first reported a position in LGND in Q1 2016 and held it in 3 quarters. The position peaked at $2.22M in Q2 2016. 269 funds tracked by Wall St. Rank hold LGND as of Q4 2016.

  • Waddell & Reed Financial reported no remaining Ligand Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Waddell & Reed Financial sold 29,816 Ligand Pharmaceuticals shares in Q4 2016, an estimated $1.9M.
  • Waddell & Reed Financial first reported a position in Ligand Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Waddell & Reed Financial's Ligand Pharmaceuticals position peaked at $2.22M in Q2 2016.
  • 269 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2016.

Based on Waddell & Reed Financial's 13F filing for Q4 2016, filed 14 Feb 2017.